Background {#Sec1}
==========

In North America, fleas, mosquitoes and ticks are considered the most important vectors for transmission of a spectrum of infectious agents that can induce disease in mammalian species, including dogs and humans; however, with the exceptions of *Dirofilaria immitis* (mosquito-borne feline heartworm disease) \[[@CR1]\], *Cytauxzoon felis* (tick-borne feline cytauxzoonosis) \[[@CR2]\] and *Bartonella henselae* (flea or tick-borne feline bartonellosis) \[[@CR1]\], other known canine and human tick-borne pathogens have not been detected in, or have been minimally studied, in cats in the US and throughout much of the world when compared to dogs or humans. *Anaplasma*, *Borrelia* and *Ehrlichia* species infect cows, sheep, dogs, horses and human beings; however, the role of these pathogens as a cause of disease in cats remains incompletely defined \[[@CR3]\]. As compared to dogs and humans, the smaller number of FVBP studies may be due to the lack of standardized serological tests, either ELISA or IFA, as are used routinely in canine veterinary practices. Also, veterinarians' perception of the risk of FVBD may be a factor because there have been fewer research studies defining the regional serological or PCR prevalence of anaplasmosis, ehrlichiosis, and Lyme disease in cats. This factor is undergoing rapid change as researchers around the world have begun to investigate FVBP prevalence among various cat populations (feral, healthy, sick, etc.). Serological, and to a lesser extent molecular-based, FVBP studies have been reported from the US \[[@CR4]--[@CR6]\], Brazil \[[@CR7]--[@CR9]\], France \[[@CR10]\], Portugal \[[@CR11]\], Italy \[[@CR12]\] Spain \[[@CR13], [@CR14]\], Sweden \[[@CR15]\], Kenya \[[@CR16]\], and the Far East \[[@CR17], [@CR18]\]. In parts of Spain and Italy, stray and domestic cat *A.phagocytophilum* seroprevalence rates ranged from 2--8 % \[[@CR7], [@CR19], [@CR20]\]. In the US, *A.phagocytophilum* seroprevalences range from 4.3 % \[[@CR6]\] in southeastern US to as high as 38 % in northeastern US endemic regions \[[@CR5]\]. *E.canis* seroprevalence rates have ranged from 6--18 % in Europe \[[@CR7], [@CR13], [@CR14], [@CR19], [@CR20]\]. In the Western hemisphere fewer *Ehrlichia* spp. seroprevalence studies have been performed; however, *E.canis* seroprevalence was 5.5 % amongst 200 domestic cats in Brazil \[[@CR8]\]. *B.burgdorferi* seroprevalence rates as high as 47 % were found in cats from areas endemic for Lyme in the US \[[@CR5]\]. Currently, veterinary diagnostic serological assays rely upon *A.phagocytophilum, B.burgdorferi* and *E.canis* antigens and assays that were originally validated for testing dogs and in most instances have not been optimized for testing cats.

Molecular-based evidence, such as PCR, indicates that cats can potentially be infected with *A.phagocytophilum* \[[@CR4], [@CR12], [@CR15]\]*, A.platys* \[[@CR21], [@CR22]\] and *E.canis* \[[@CR9], [@CR11], [@CR23]--[@CR25]\]. In Sweden, Bjoersdorff *et al.* was first to report PCR amplification of *A.phagocytophilum* from a cat \[[@CR15]\]. The DNA sequence in a 14-month-old shorthaired cat with lethargy and fever was 100 % identical to dog and horse *A.phagocytophilum* strains from the same region. Subsequently, Lappin *et al.* confirmed infection with *A.phagocytophilum* in 5 young clinically-ill cats from the northeastern US by PCR amplification and DNA sequencing \[[@CR4]\]. To date, *A.platys* infections, with PCR amplification of the pathogen, have been reported in only two thrombocytopenic cats \[[@CR21], [@CR22]\]. Other clinical manifestations included anorexia and platelet inclusion bodies in a cat from Brazil \[[@CR21]\] and chronic hyperglobulinemia in a cat from North Carolina that was also PCR positive for *Mycoplasma hemominutum, Bartonella henselae* and *Bartonella koehlerae* \[[@CR22]\]. Using PCR, *Ehrlichia* species DNA has been amplified from cats located in Italy \[[@CR12]\], France \[[@CR10], [@CR23]\] and the Americas \[[@CR8], [@CR9], [@CR23]--[@CR25]\]. DNA evidence of possible *E.canis* (98 % identity) and *E.chaffeensis* (97 % identity) infections was reported by Braga Mdo *et al.* in cats from Brazil \[[@CR8]\]. Positive *E.canis* PCR results were also reported for 11 thrombocytopenic and lymphopenic Brazilian cats \[[@CR9], [@CR25]\]. Based upon PCR amplification and DNA sequencing of the *Ehrlichia 16S* rDNA gene, our research group described *E.canis* infection (100 % identical to *E.canis* DNA obtained from dog isolates) in cats from France \[[@CR23]\] and in 3 young, sick cats from the southeastern United States or eastern Canada \[[@CR24]\].

IDEXX Laboratories, Inc. (Westbrook, Maine, USA) developed a qualitative enzyme-linked immunosorbent assay (ELISA) test, SNAP® M-A, using *Anaplasma* genus EENZ1 and *Ehrlichia* genus p30/p30-1 peptides to broadly detect *Anaplasma* spp. and *Ehrlichia* spp. antibodies in conjunction with *A.phagocytophilum* p44 Aph, *A.platys* p44 Apl*, E.canis* p16*, E.chaffeensis* VLPT*, E.ewingii* p28, and *B.burgdorferi* C6 species-specific peptides as a research tool to characterize regional trends in seroprevalence to specific vector-borne pathogens in dogs \[[@CR26], [@CR27]\]. Although developed as a canine assay, the assay does not use a host species-specific conjugate, and can therefore be used on a research basis to screen mammalian species other than dogs. An earlier ELISA based assay, the SNAP® 3Dx®, was used in a serosurvey of cats naturally exposed to *B.burgdorferi* \[[@CR28]\] and the SNAP®4Dx® has been utilized to test horses for borreliosis \[[@CR29]\] and ehrlichiosis \[[@CR30], [@CR31]\]. Recently, Qurollo *et al.* reported seroprevalence data using SNAP® M-A in over 6500 archived canine serum samples from the US, Canada and the Caribbean. Overall and regional seroprevalence and co-seroprevalence (exposure to more than one pathogen) was determined, as well as seroprevalence trends between 2008 and 2010 \[[@CR26]\]. Although currently SNAP® M-A is not available commercially, the use of a broad range of genus and species-specific immunodominant peptides in diagnostic tests would allow veterinarians to determine *Anaplasma* or *Ehrlichia* species exposures in dogs and cats in their region. This information could benefit both clinical decision making, as well as human and veterinary zoonotic disease education \[[@CR32]--[@CR34]\].

The purpose of this study was to evaluate a wide range of FVBPs in cats suspected of exposure to a vector-borne pathogen. Specifically, we determined the seroprevalence of *Anaplasma* spp*., B.burgdorferi* and *Ehrlichia* spp. and the presence of *Anaplasma* or *Ehrlichia* sp. DNA, as determined by PCR amplification and DNA sequencing.

Methods {#Sec2}
=======

All samples were de-identified, so no ethical approval necessary.

Clinical accessions and sample availability {#Sec3}
-------------------------------------------

Feline clinical accessions (*n* = 858) submitted to the NCSU-CVM-VBDDL between January 1, 2008, and December 31, 2013, for FVBP testing originated from veterinary hospitals located in the United States (*n* = 827), Canada (*n* = 28) and the Caribbean (*n* = 3). Sample submission information included date of collection, date received, and the cat owner or veterinary practice address while individual identifications were not revealed. Of these 858 cats, 715 sera were available for testing using the SNAP® M-A kit for *Anaplasma, Borrelia, and Ehrlichia* antibodies and EDTA-anti-coagulated whole blood was available from 406 cats for PCR testing. Prior to the study, *Anaplasma* and *Ehrlichia* diagnostic PCR results were known for 163 of these 406 cats. Stored, frozen (−80 °C) blood was retrievable for additional PCR testing for 331/406 diagnostic accessions. When adequate serum volumes were available, a subset of 59 SNAP® M-A seropositive and 4 PCR positive samples were tested by SNAP®4Dx®Plus assay (IDEXX Laboratories, Inc. Westbrook, Maine, USA) and by indirect fluorescent antibody (IFA) assays using whole cell antigens. Medical record data was obtainable for 7 PCR positive cats, 4 of which were referrals to the NC State Veterinary Hospital and 3 were from other veterinary hospitals or universities. Medical records were reviewed for the signalment, history and physical examination findings, complete blood count (CBC), serum biochemistry profile abnormalities and for additional diagnostic testing that were performed, including abdominal ultrasound, radiographs, or coagulation profiles.

### Serological assays {#Sec4}

Cat serum specimens (*n* = 715) were retrospectively tested by SNAP® M-A for *A.phagocytophilum*, *A.platys*, *B.burgdorferi, E.canis*, *E.chaffeensis*, and *E.ewingii* antibodies. This kit uses a reversible chromatographic flow of sample and automatic, sequential flow of wash solution and enzyme substrate. Archived cat serum stored at − 80 °C was thawed to room temperature prior to mixing 4 drops of serum with 4--5 drops of SNAP® M-A conjugate. The mixture was allowed to move across a flow matrix where peptide-specific antibody could bind to peptide-horse radish peroxidase conjugate before color reactant release. Color development, indicating a positive reaction, was read after 15 min per manufacturer's instructions (IDEXX Laboratories, Inc, Westbrook, Maine, USA).

### PCR testing {#Sec5}

DNA from 200 μL of feline EDTA-anti-coagulated whole blood was extracted with a QIAsymphony™ robotic extractor using MagAttract® DNA Mini M48 kit (Qiagen, USA cat: 953336). DNA quality was assayed by quantitative PCR (qPCR) amplification of the glyceraldehyde 3-phosphate dehydrogenase gene on feline genomic DNA. A conventional PCR assay targeting a conserved region of the *Anaplasma* and *Ehrlichia 16S* rRNA gene \[[@CR35]\] and two qPCR assays targeting the *Anaplasma* genus *Tr-1* and *Ehrlichia* genus *sodB* \[[@CR36]\] genes were performed on stored, frozen blood samples (*n* = 331). Species were identified by amplicon sequencing (Genewiz, Research Triangle Park, NC, USA) and additional, species-specific qPCRs were used in an attempt to confirm positive samples. The *Anaplasma* genus *Tr-1* assay and species-specific assays (*A.phagocytophilum p44, A.platys p44, E.chaffeensis nadA, and E.ewingii sodB*) used in this study have not been previously reported; primer sequence and amplicon size for each of these qPCRs are listed in Table [1](#Tab1){ref-type="table"}. The reactions were performed in a CFX96™ Real-Time Detection System combined with C1000™ Thermal Cycler (Bio-Rad, USA) under the following conditions: 25 μl final volume reaction containing 12.5 μl of SYBR®Green Supermix, 0.2 μM of the *Tr-1* primers and 0.3 μM of each species-specific primer (Sigma-Aldrich, St Louis, MO, USA), 7 μl of filter-sterilized, molecular-grade water and 5 μl of DNA template. Thermocycler conditions consisted of a single cycle at 98 °C for 2 min, followed by 40 cycles of denaturation at 98 °C for 15 s, annealing at 57 °C (*Tr-1*) or 67 °C (all species-specific assays) for 15 s, and extension at 72 °C for 15 s. Melting temperature measurements were made between 65--88 °C at 0.5 s intervals.Table 1Primer targets, sequences and amplicon base pair size for previously unreported quantitative PCR assays used in this study. F: Forward primer; R: reverse primerTargetPrimersAmplicon (bp)*Anaplasma -tr-1*F- 5′ ATGTTTATGACTTCTCAAGCAC-3′ R- 5′ CCC TTT TCG TAT TTT TGT AC-3′200*A. phagocytophilum -p44*F- 5′ TGGTGGTGCGGGATATTTCTATGTTG-3′ R- 5′ CCCAATCCGAGGATCAGGTGTG-3′179*A. platys -p44*F- 5′ GCT AAG TGG AGC GGT GGC GAT GAC AG-3′ R- 5′ GCCGCAGTTTCCCCGGTACT-3′179*E. chaffeensis -nadA*F- 5′ CGCAAAAGATGTAATTCTTTGGGAATC-3′ R- 5′ CACCTCAAAATCAGAATTCATCGAAGG-3′117*E. ewingii -sodB*F- 5′ GCTGGAATAGGTCATTTTGGTAGTGGA-3′ R- 5′ GTTCCCATACATCCATAGCAAGCAAC-3′147

### Comparison of serological assays {#Sec6}

Fifty-nine stored, frozen sera from SNAP® M-A seropositive and/or PCR positive cats were retested using the SNAP®4Dx®Plus assay (IDEXX Laboratories, Inc. Westbrook, Maine, USA) according to manufacturer's directions. SNAP® M-A and PCR positive cats were also tested by IFA using *A.phagocytophilum* (ProtaTek International Inc. St. Paul, MN, USA), *E.canis* (strain NC Jake), *E.chaffeensis* (strain *E.chaffeensis* Ark) and *B.burgdorferi* (MBL Bion, Des Plaines, IL, USA) antigen slides as appropriate for the seroreactivity detected by SNAP® M-A. For IFA testing, serum samples were diluted two fold from 1:16 to 1:512 in phosphate buffered saline (PBS) solution containing 1 % normal goat serum, 0.05 % Tween-20 and 0.5 % powdered nonfat dry milk (BioRad, Hercules, CA, USA). Antibody responses were detected by IFA with fluorescein conjugated goat anti-cat IgG (Thermo Fisher Scientifics, Waltham, MA, USA) \[[@CR37]\]. Seropositive samples were defined as having endpoint titers ≥ 1:64 based upon laboratory criteria used by the VBDDL.

Results {#Sec7}
=======

Seroreactivity {#Sec8}
--------------

Of the 715 cat serum samples tested with SNAP® M-A, the overall FVBP seroprevalence (Table [2](#Tab2){ref-type="table"}) was 7.8 % (56/715) with *B.burgdorferi* the most seroprevalent at 5.5 % (39/715). By SNAP® M-A testing, seroreactivity to an *Anaplasma* or *Ehrlichia* spp. peptide was detected in 2.9 % (21/715) of cat serum accessions tested. Based upon the 3 *Anaplasma* spp. analytes, 1.8 % of cats (13/715) were exposed to an *Anaplasma* spp., of which 12 were *A.phagocytophilum* seroreactive and one cat was seroreactive with only the genus analyte. No cat was SNAP® M-A *A.platys* seroreactive. Using SNAP® M-A, *Ehrlichia* genus seroreactivity was found in 1.7 % (12/715) of cats. Based upon reactivity to a species-specific peptide, 5 of the 12 cats were seroreactive to *E.canis* (0.7 %), 2 cats to *E.ewingii* (0.3 %),1 cat to *E.chaffeensis* (0.2 %) and 4 cats were seroreactive with only the genus analyte. Seroreactivity to more than one FVBP was found in 16.1 % (9/56) of seroreactive cats. For each of these 9 cats, *B.burgdorferi* seroreactivity was detected in conjunction with either *A.phagocytophilum* (*n* = 7) or *E.ewingii* (*n* = 2) seroreactivity.Table 2Regional Seroprevalence by SNAP® M-A shown as percentages of 715 feline serum samplesRegions*Anapl* genus*AphAplBbEhrl* genus*EcEchEew*Northeast *n* = 187 (26 %)2^a^9 (6^a^)026 (6^a^)0200Mid Atlantic *n* = 59 (8 %)2 (1^a^)2010 (3^a^)1002^a^South *n* = 284 (40 %)11013110Midwest *n* = 114 (16 %)01011000West *n* = 42 (6 %)00000100Canada *n* = 26 (4 %)00000100Caribbean *n* = 3 (0.4 %)00010000Total *n* = 7155 (0.7 %)13 (1.8 %)039 (5.5 %)5 (0.7 %)5 (0.7 %)1 (0.2 %)2 (0.3 %)^a^indicates co-exposures*Anapl* genus: *Anaplasma* genus*; Aph*: *A.phagocytophilum*; *Apl*: *A.platys*; *Bb*: *Borrelia burgdorferi*; *Ehrl* genus: *Ehrlichia* genus; *Ec*: *E.canis*; *Ech*: *E.chaffeensis*; *Eew*: *E.ewingii*

PCR amplification of *Anaplasma* and *Ehrlichia* {#Sec9}
------------------------------------------------

Based upon conventional *Anaplasma* and *Ehrlichia 16S* rDNA PCR diagnostic results, performed at the time of sample submission to the VBDDL (*n* = 163), 7 cats were infected with either *A.phagocytophilum* (*n* = 4), *A.platys* (*n* = 2), or *E.canis* (*n* = 1). When archived frozen EDTA-whole blood (*n* = 331) was accessed for testing by *16S* rDNA PCR, 7 cats were infected with either an *Anaplasma* or *Ehrlichia* spp., including *E.ewingii* (*n* = 3), *E.chaffeensis* (*n* = 2), *A.phagocytophilum* (*n* = 1) and *A.platys* (*n* = 1). Based upon diagnostic and archival PCR testing, the total number of cats infected with an *Anaplasma* or *Ehrlichia* sp. was 3.2 % (13/406), with one *A.phagocytophilum* PCR positive cat represented in both the diagnostic and archival PCR results (Table [3](#Tab3){ref-type="table"}). Additional retrospective *Anaplasma* and *Ehrlichia* genus- and species-specific PCRs confirmed several *16S* rDNA PCR positive samples, and included cats infected with *A.phagocytophilum*, *E.chaffeensis*, and *E.ewingii* (Table [3](#Tab3){ref-type="table"}).Table 3State of origin, VBDDL diagnostic and archived sample Anaplasma and Ehrlichia PCR results, SNAP® M-A, SNAP® 4Dx®Plus and IFA (antigen) serology results for individual cats infected with FVBDCat \#US state of sample originVBDDL diagnostic PCR (gene targets)PCR on archived samples (gene targets)SNAP® M-ASNAP® 4Dx® PlusIFA (*Ech*)IFA (*Ec*)IFA (*Aph*)IFA (*Bb*)1NC*Apl (16S, GroEL, p44)*N/A(−)N/AN/AN/AN/AN/A2OH*Apl (16S)*N/AN/AN/AN/AN/AN/AN/A3NCND*Apl (16S)*N/AN/AN/AN/AN/AN/A4MI*Aph (16S)*(−)N/AN/AN/AN/AN/AN/A5MA*Aph (16S)*(−)N/AN/AN/AN/AN/AN/A6NC*Aph (16S)*(−)N/AN/AN/AN/AN/AN/A7NY*Aph (16S)Aph (16S, tr-1, p44)Bb+Bb+*64\<16\<16328VA*Ec (16S)*(−)N/AN/AN/AN/AN/AN/A9NC(−)*Ech (16S)*(−)(−)\<16\<16\<1612810MOND*Ech (16S, sodB, nadA)*(−)(−)\<16128\<161611SC(−)*Eew (16S)*(−)(−)\<16\<16\<161612CA(−)*Eew (16S)*(−)(−)\<16\<16\<16\<1613NC(−)*Eew (16S, sodB)*N/AN/AN/AN/AN/AN/A*Aph*: *A.phagocytophilum*; *Apl*: *A.platys*; *Ec*: *E.canis*; *Ech*: *E.chaffeensis*; *Eew*: *E.ewingii*; *Bb*: *B.burgdorferi*; FVBD: feline vector-borne disease; ND: not done; N/A: Archived Serum or EDTA-whole blood was not available; (−): negative serology or PCR result

Clinical data {#Sec10}
-------------

Clinical data for 7 PCR positive cats is summarized in Table [4](#Tab4){ref-type="table"}. The FVBP PCR positives for which records were available included 3 *A.platys* infected cats, one of which was a cat diagnosed with multiple myeloma, as previously described in a case report \[[@CR22]\], 2 *A.phagocytophilum* infections, 1 *E.chaffeensis* infection (limited to CBC and biochemistry panel), and 1 *E.ewingii* infection. Four of the 6 cats were reported as being indoor/outdoor, 2 were indoor only, one unknown, and one cat had a tick removed immediately prior to becoming ill. Presenting complaints included anorexia, lethargy or epistaxis. Three cats were febrile at the time of physical examination and one cat was icteric, however this cat was co-infected with *Cytauxazoon felis* and *A.platys*. Feline Leukemia and Feline Immunodeficiency Virus (FeLV/FIV) results were negative for 6 of 6 cats tested. The most common hematological abnormalities included anemia (*n* = 5), thrombocytopenia (*n* = 5) and neutrophilia (*n* = 3). Other blood abnormalities reported by the attending veterinarian included hyperglobulinemia, lymphocytosis or thrombocytosis. One *E.ewingii* positive cat was found to be hyperthyroid.Table 4Abbreviated clinical data available for 7 Anaplasma or Ehrlichia PCR positive catsCat\#FVBDSig.Presenting complaintAbnormal PE findingsHematologicalAdditional findings1*Apl*11y MC DSHchronic hyper-globulinemianone reportedmod. hyperglobulinemia, mld. thrombocytopenia mld. anemiaindr/outdr; FeLV/FIV (−); co-infection with *Mh*, *Bh*, and *Bk*; dx. with multiple myeloma\*2*Apl*3y MC DSHlethargy, pallorpale, febrile (103.5 °C), heart murmur (IV/VI)svr. anemia, mld leukocytosis mod. lymphocytosisindr/outdr; FeLV/FIV (−); saline ag.(−); imaging: enlarged heart and mld. free fluid in thoracic and abdominal cavities; BM aspirate erythiroid hyperplasia and dysplasia, lymphoid hyperplasia; dx. PRCA or infection or CLL.3*Apl*5y FS DMHanorexia, lethargy, *C. felis* (+)icteric, febrile (103.2 °C)svr. anemia, mld. leukopenia mod. thrombocytopenia, mld. hyperproteinemiaindr/outdr; FeLV/FIV (−); normal coag-ulation (PT/PTT); co-infection *C. felis*6*Aph*8 m MC DSHlethargy, persistent leukocytosisnone reportedmod. neutrophilia, mod. lymphocytosis, mod. thrombocytosisindr; FeLV/FIV (−); imaging WNL7*Aph*9y MC DSHlethargy, inappetancelethargic, febrile (103.5 °C)mld. anemia, mod. thrombocytopenia mod. neutrophilia mod. lymphopeniaindr/outdr; tick removed recently; FeLV/FIV (−); normal coagulation (PT/PTT)9*Ech*11y MC DSHNDNDWNLND13*Eew*12y MC DSHchronic intermittent epistaxisepistaxis thyroid nodulemod. anemia mld. neutrophilia svr. thrombocytopenia elevated T4indr/outdr; FeLV/FIV (−); normal coagulation (PT/PTT); imaging WNL*Aph*: *A.phagocytophilum*; *Apl*: *A.platys*; *Ech*: *E.chaffeensis*; *Eew*: *E.ewingii*; PE: physical examination; MC: male castrated; FS: female spayed; DS(M)H: domestic short (medium) hair; mld: mild; mod: moderate; svr: severe; indr: indoor; outdr: outdoor; WNL: within normal limits; ND: no data; FeLV: Feline Leukemia Virus; FIV: Feline Immunodeficiency Virus; BM: Bone Marrow; PRCA: pure red cell aplasia; CLL: Chronic Lymphoid Leukemia; PT: Prothrombin Time; PTT: Partial Thromboplastin Time. \*previously reported case report \[[@CR22]\]

Comparison among serological assays {#Sec11}
-----------------------------------

Fifty-nine SNAP® M-A positive serum samples had sufficient volume for SNAP®4Dx®Plus and/or IFA comparative testing. Of the 13 cats that were seroreactive to SNAP® M-A *Anaplasma* sp. analytes (EENZl and P44 Aph), only 3 (23 %) were seroreactive by SNAP®4Dx®Plus (EENZ1 analyte), whereas 11 (85 %) were IFA positive for *A.phagocytophilum* antibodies. When compared to the SNAP® M-A *Ehrlichia* sp. analytes (p30/p30-1, p16, VLPT, p28), there was variable agreement with the SNAP®4Dx®Plus and *E.chaffeensis* or *E.canis* IFA using whole cell antigen preparations (Table [5](#Tab5){ref-type="table"}). By *E.chaffeensis* IFA, only one *E.chaffeensis* and one *Ehrlichia* genus reactive cat were seropositive at titers of 1:256 and 1:64, respectively. Only the *E.chaffeensis* IFA seroreactor was *E.canis* IFA seroreactive at a titer of 1:256. None of the five SNAP® M-A *E.canis* p16 reactors were positive by SNAP®4Dx®Plus (p16 not present in this assay) or by IFA testing using *E.chaffeensis* or *E.canis* whole cell antigens. Of the 39 SNAP® M-A *B.burgdorferi* C6 peptide positives, 23 (59 %) and 27 (69 %) were positive by SNAP®4Dx®Plus or a whole cell *B.burgdorferi* antigen preparation, respectively.Table 5Comparison of SNAP® M-A results for 59 sera with SNAP®4Dx®Plus and Anaplasma phagocytophilum, Ehrlichia chaffeensis, Ehrlichia canis, or Borrelia burgdorferi Immunofluorescence results\# SNAP® M-A positive\# SNAP®4Dx®Plus positive\# IFA seroreactive ≥ 64SNAP® M-A Analyte*A.phagocytophilumA.* genus eenz153/53/5*Aph* p44 aph123/129/12*Apl* p44 apl000*E.chaffeensisE.canisE.* genus p30/p30-154/52/51/5*Ec* p1650/50/50/5*Ech* VLPT11/11/11/1*Eew* p2821/21/20/2*B.burgdorferiBb* C63923/3927/39IFA: immunofluorescent assay; *A.*genus*: Anaplasma spp.; E.*genus*: Ehrlichia spp.; Aph*: *A. phagocytophilum*; *Apl*: *A.platys*; *Ec*: *E.canis*; *Ech*: *E.chaffeensis*; *Eew*: *E.ewingii*; *Bb*: *B. burgdorferi*

Serum samples, available for 4 PCR positive cats, (2 *E.chaffeensis* and 2 *E.ewingii*) were not seroreactive by any of the three serological assays with the exception of an antibody response of 1:128 against *E.canis* by IFA for a cat that was PCR positive for *E.chaffeensis* (Table [3](#Tab3){ref-type="table"}). A serum sample available from a fifth cat PCR positive for *A.phagocytophilum* was reactive to the C6 *B.burgdorferi* analyte in both SNAP® M-A and SNAP®4Dx®Plus but was not reactive to any *A.phagocytophilum* antigens.

Discussion {#Sec12}
==========

To the authors' knowledge, this is one of the largest feline tick-borne pathogen prevalence studies reported for cats suspected of vector-borne infections from North America. Using species-specific peptides or PCR testing, this study identified two tick-borne pathogen species (*E.chaffeensis* and *E.ewingii)* that to our knowledge have not been previously reported to infect cats in North America. In addition, antibodies to *B.burgdorferi* (5.5 %) and *A.phagocytophilum* (1.8 %) were found frequently in serum submitted from sick cats in Lyme disease endemic regions of the northeastern and mid-Atlantic United States. These two pathogens share a common vector, *Ixodes scapularis*. Similarly, *B.burgdorferi* and *A.phagocytophilum* co-exposures were the most frequently detected. While exposure to, or infection with, a spectrum of FVBP were identified among these cats, the overall serological and PCR prevalence of tick-borne infections were relatively low compared to dogs tested during a similar time frame \[[@CR26], [@CR38]\]. For example, using SNAP® M-A to test over 6500 dog serum samples submitted to the NCSU-CVM-VBDDL from the United States, Canada and the Caribbean, primarily between 2008 and 2010, the overall canine seroprevalence was 8.3 % for *B.burgdorferi* and 3.4 % for *A.phagocytophilum,* both nearly double the prevalences in cats \[[@CR26]\]. Reasonable explanations for the lower FVBP seroprevalences include shorter tick-attachment times due to fastidious grooming, thus reducing the opportunity for pathogen transmission. Also, although demographic and environmental data was not available for these diagnostic accessions, the cats included in this study were likely client-owned and therefore were more likely to be maintained primarily indoors and thus exposed to fewer ticks than their canine counterparts.

Historical or more recent documentation of exposure to, or infections with, *A.platys, E.canis, E.chaffeensis and E.ewingii* in cats provides a justification for future studies that investigate specific disease presentations associated with each of these infections. Similar to dogs, cats can be sequentially or concurrently exposed to more than one FVBP; therefore, co-infections can influence clinical, hematological and pathological findings \[[@CR26]\]. In this study, complete or partial medical data obtained for 7 PCR positive cats (Table [4](#Tab4){ref-type="table"}) underscores potential clinical and hematological disease similarities among cats and dogs in association with vector-borne infectious diseases. For example, four of seven cats were anemic and thrombocytopenic and epistaxis was reported in one of the markedly thrombocytopenic *E.ewingii* infected cats. Also, two *A.platys* infected cats were thrombocytopenic; however, co-infections were detected in both cats, so it is impossible to know the degree to which the *A.platys* infection contributed to thrombocytopenia in either cat.

In conjunction with published and ongoing studies of cat populations throughout the world, expanded FVBP test offerings by diagnostic laboratories are warranted. The sensitivity of a serological test is contingent upon the type, configuration and specificity of peptides chosen in the design of the assay. In addition, it should be determined if cats' immunological reactivity to currently used diagnostic peptides is the same or different than dogs. Although assays being used in canine VBD diagnostic panels, whether ELISA or IFA based, will be a first step in facilitating the detection of FVBP in cats, improvements are in order. As an example, five cats were seroreactive using the *E.canis* p16 peptide, whereas none of these 5 cats were seroreactive by SNAP®4Dx®Plus (p16 not present in this assay) or by IFA testing using *E.chaffeensis* or *E.canis* whole cell antigens. Whether this discrepancy represents a lack of specificity of the p16 analyte, a lack of sensitivity of the commercial ELISA and IFA, or enhanced analytical sensitivity of this analyte for testing cat sera remains to be determined. Also, only one of the *E.chaffeensis* or *E.ewingii* infected cats (PCR+ with DNA sequence confirmation) was seroreactive, using any of the three assays assessed in this study. If as a general rule applicable to tick exposed cats, this finding could contribute to falsely low *Ehrlichia* seroprevalences, both diagnostically and during cat serosurvey studies. Isolation of FVBP from cats in conjunction with the detailed characterization of immunologic response to specific antigens may lead to assays that are more specific and hopefully more sensitive in the clinical diagnosis of acute or chronic vector-borne diseases in cats. The combination of serology and PCR testing has been recommended for the evaluation of canine VBDs \[[@CR39]\]. Based upon the results of this study, using panels combining serology, with IFA being demonstrated as slightly more sensitive than ELISA in this study for *A.phagocytophilum, Ehrlichia spp.,* and *B.burgdorferi*, along with genus and species-specific PCR in cats seems warranted, as this approach would facilitate more accurate diagnoses and targeted therapy for sick cats.

There were several inherent limitations to this study. The cat serum and blood specimens submitted by veterinarians to the VBDDL were from cats presumably suspected of an infection with a FVBP. However, based upon the historical research priorities of our laboratory, it is likely that many of these specimens were submitted from cats in which cytauxzoonosis (*C. felis* transmitted by ticks) or bartonellosis (*Bartonella henselae* and other *Bartonella sp.* most often transmitted by fleas) were suspected. Thus, seroprevalence rates in these cats are presumably higher than in the healthy, client-owned cat population. Although cats were regionalized based on local veterinary hospitals or owner zip codes, individual travel histories were not available; therefore, where exposures or infections occurred remains uncertain. Also, as medical histories were not provided in conjunction with sample submission information, it was not possible to determine risk factors such as outdoor exposure potential (living primarily indoors, indoors and outdoors, or outdoors only), vector exposure and other environmental factors that would influence the prevalence results. Despite obtaining clinical data for 7 PCR positive cats; incomplete medical record entries, variability in the clinical data obtained for each cat and the documentation of co-infections in two cats, does not allow specific clinical or hematological abnormalities to be attributed to infection with a specific FVBP.

Conclusions {#Sec13}
===========

Cats are exposed to and can be infected with vector-borne pathogens that commonly infect dogs and humans. *Anaplasma phagocytophilum, A.platys*, *E.canis*, *E.chaffeensis* and *E.ewingii* infections were confirmed by PCR amplification and DNA sequencing. To our knowledge, this study provides the first evidence for *E.chaffeensis* and *E.ewingii* infection in naturally-exposed cats in North America. Results from this study support the need for regional, serological and molecular FVBP prevalence studies, the need to further optimize serodiagnostic and PCR testing for cats, and the need for prospective studies to better characterize clinicopathological disease manifestations in cats infected with FVBP.

FVBP

:   Feline vector-borne pathogens

VBDDL

:   Vector-Borne Disease Diagnostic Laboratory

NCSU-CVM

:   North Carolina State University-College of Veterinary Medicine

SNAP® M-A

:   SNAP® Multi-Analyte Assay

qPCR

:   quantitative PCR

ELISA

:   Enzyme-linked immunosorbent assay

EDTA

:   Ethylenediaminetetraacetic acid

IFA

:   Immunofluorescent antibody

CBC

:   Complete blood count

FeLV/FIV

:   Feline leukemia / Feline immunodeficiency virus

PBS

:   Phosphate buffered saline
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